Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plastic Surgery Market: Fat Grafting Grabs A Hefty Slice Of The Plastics Pie

Executive Summary

Fat, fillers, and a "funnel" that may minimize a common cause of breast implant complications are among the hot topics in both aesthetic and reconstructive plastic surgery. Meanwhile, the acquisition by Actavis of Allergan – a leading player in the aesthetics market with BOTOX and breast implants – has the combined company poised for long-term double-digit revenue and earnings growth.

You may also be interested in...



Facial Aesthetics Market: New Technologies Address Consumer Demand

Consumers of aesthetic procedures are still looking for the perfect option – one that produces a more youthful looking face, but does not require much, if any, downtime. Ideally, these consumers also would like something that offered a long-lasting effect and was delivered with minimal pain and discomfort. At the 2011 AAFPRS conference, held recently in San Francisco, CA, the Emerging Trends and Technologies session focused on new and developing technologies that could meet some of these demands.

How Europe’s Nomenclature System Works And Offers New Insights

Transparency linked to new device registration rules will provide new market analysis possibilities. Medtech Insight delved deeper into the benefits of the European Medical Device Nomenclature with two Italian executives who see its potential.

MHRA Offers Medtechs Extra Transition Time For UK Regulatory System Compliance

26 June saw the release finally of the UK government’s official response to the MHRA’s 2021 consultation on its post-Brexit medical devices regulatory framework. The considered response, held up by political and internal timing issues, represents an implementation plan for reform of the system. Crucially it allows industry extra compliance time.

Topics

Related Companies

Related Deals

Latest News
UsernamePublicRestriction

Register

MT035722

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel